These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4060747)

  • 1. Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: 72 months of life-table analysis and steroid hormone receptor status.
    Rose C; Mouridsen HT; Thorpe SM; Andersen J; Blichert-Toft M; Andersen KW
    World J Surg; 1985 Oct; 9(5):765-74. PubMed ID: 4060747
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.
    Rose C; Thorpe SM; Mouridsen HT; Andersen JA; Brincker H; Andersen KW
    Breast Cancer Res Treat; 1983; 3(1):77-84. PubMed ID: 6347277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant endocrine treatment of postmenopausal patients with breast cancer with high risk of recurrence. 5. Results from the DBCG (Danish Breast Cancer Cooperative Group) 77C randomized trial].
    Rose C; Andersen JA; Andersen KW; Axelsson CK; Blichert-Toft M; Dombernowsky P; Hansen M; Krag C; Mouridsen HT; Overgaard M
    Ugeskr Laeger; 1991 Aug; 153(33):2283-7. PubMed ID: 1781047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic therapy in primary breast cancer.
    Mouridsen HT; Palshof T
    Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
    [No Abstract]   [Full Text] [Related]  

  • 7. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.
    Rose C; Thorpe SM; Andersen KW; Pedersen BV; Mouridsen HT; Blichert-Toft M; Rasmussen BB
    Lancet; 1985 Jan; 1(8419):16-9. PubMed ID: 2856949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
    Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
    Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
    [No Abstract]   [Full Text] [Related]  

  • 9. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
    Rutqvist LE; Cedermark B; Fornander T; Glas U; Johansson H; Nordenskjöld B; Rotstein S; Skoog L; Somell A; Theve T
    J Clin Oncol; 1989 Oct; 7(10):1474-84. PubMed ID: 2674335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [For postmenopausal women with hormone-dependent tumors. Aromatase inhibitors are the new gold standard].
    Jonat W
    MMW Fortschr Med; 2006 Mar; 148(12):10. PubMed ID: 16625996
    [No Abstract]   [Full Text] [Related]  

  • 11. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
    Aihara T; Yokota I; Hozumi Y; Aogi K; Iwata H; Tamura M; Fukuuchi A; Makino H; Kim R; Andoh M; Tsugawa K; Ohno S; Yamaguchi T; Ohashi Y; Watanabe T; Takatsuka Y; Mukai H
    Breast Cancer Res Treat; 2014 Nov; 148(2):337-43. PubMed ID: 25318924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who needs steroid receptor assays?
    Barnes DM; Fentiman IS; Millis RR; Rubens RD
    Lancet; 1989 May; 1(8647):1126-7. PubMed ID: 2566061
    [No Abstract]   [Full Text] [Related]  

  • 15. [Tamoxifen therapy in locally advanced primary and recurrent breast cancer (author's transl)].
    Wada T; Koyama H; Takahashi Y; Nishizawa Y; Iwanaga T; Aoki Y; Terasawa T
    Nihon Gan Chiryo Gakkai Shi; 1979 Aug; 14(5):819-24. PubMed ID: 501187
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
    Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
    J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
    Pennery E
    Eur J Oncol Nurs; 2008 Jul; 12(3):233-43. PubMed ID: 18372213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
    Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
    Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.